AbbVie Inc (ABBV)vsPrime Medicine, Inc. Common Stock (PRME)
ABBV
AbbVie Inc
$227.23
-2.14%
HEALTHCARE · Cap: $391.50B
PRME
Prime Medicine, Inc. Common Stock
$3.06
-11.82%
HEALTHCARE · Cap: $489.47M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1557138% more annual revenue ($62.82B vs $4.03M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
PRME
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$227.23
$81.01 premium
Margin of Safety
-38.5%
Fair Value
$2.49
Current Price
$3.06
$0.57 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : PRME
PRME has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : PRME
The primary concerns for PRME are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
PRME carries more volatility with a beta of 2.31 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 19/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Prime Medicine, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Prime Medicine, Inc. is a leading biotechnology company pioneering advancements in genetic medicine through its proprietary Prime Editing technology, which facilitates precise DNA modifications. The company has developed a robust pipeline aimed at addressing severe diseases, including genetic disorders and various cancers, positioning it to meet substantial unmet medical needs. With a strong foundation of intellectual property and a clear vision for transformative therapeutic solutions, Prime Medicine is positioned for significant growth, potentially redefining treatment paradigms within the biopharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?